That reduced principal by $41.4 million generated the $4.6 million gain I mentioned and lowers our annual interest expense by approximately $4 million. Our term loan now stands at $423.6 million, a reduction of more than 70% from the $1.6 billion we carried before our financial reorganization. Even as we continue to proactively pay down this loan, we retain the liquidity to invest in the strategic priorities that will define the company's future. Now to our outlook. We are reaffirming our previously provided 2026 guidance for revenue of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million. We continue to expect clinical subscription revenue to represent 25 to 30% of 2026 total revenue, up from 15.9% for the full year 2025. This growth incorporates moderate declines in clinical subscribers in the remaining quarters, primarily due to lower marketing spend levels, a more balanced allocation of marketing resources across our lines of business following the more concentrated clinical focus in Q1 2026, and the lapping of our 12-month long-term commitment plan introductions. Q3 is our lowest quarter in terms of marketing spend, and spending will ramp up in Q4 ahead of peak season consistent with our typical seasonal cadence. Within behavioral, we expect continued year-over-year growth in Core Plus subscribers and continued moderation in the year-over-year rate of behavioral end-of-period subscriber decline. On growth margin, we continue to expect a modest adjusted growth margin decline in 2026 versus 2025, and we expect to remain above 72%. On operating expenses, we expect 2026 marketing expense as a percentage of revenue to increase modestly compared to 2025, with second half spend below first half levels. We expect product development to remain near the Q2 quarterly run rate. On cash, with peak marketing investment behind us, we are very confident that we will generate cash and expect positive operating cash flow for the full year 2026. We expect approximately 45 million to 50 million of interest costs for the full year, reflecting lower quarterly interest following the Q2 prepayment, quarterly capitalized software and development in line with Q2 run rate, and 2026 cash taxes of between $5 million and $10 million. Our second quarter results demonstrate the earnings power of our more disciplined operating model. We are seeing clear signs of progress toward the higher value mix shift we have been targeting, with Core Plus delivering its third consecutive quarter of sequential subscriber growth and Clinical continuing to grow as a share of total revenue. As Core Plus and Clinical become a larger share of our business, we see a company built on a stronger financial foundation with a meaningfully smaller debt load and positive operating cash flow supporting strategic investment in our transformation. We head into the second half with confidence in the multi-year plan we have laid out and in the team executing upon it. I will now turn it over to the operator to open it up for Q&A.

We will now begin the question and answer session. To ask a question, you may press star then 1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster. At this time, there are no questions. I would like to hand it back over to Felicia for closing remarks.

Thank you all for joining us today. Weight Watchers exist to ensure that no one has to navigate their weight health journey alone, and we remain singularly focused on executing against that mission. We look forward to continuing to update you on our progress. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.